FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296033> ?p ?o ?g. }

• W4286296033 endingPage "e14555" @default.
• W4286296033 startingPage "e14555" @default.
• W4286296033 abstract "e14555 Background: Metastasis is responsible for most cancer-related deaths and depends on the formation of a metastatic niche at distal sites. The metastatic niche consists primarily of immunosuppressive myeloid cells, such as neutrophils and monocytes. These cells are recruited to distal sites in response to cancer-induced immune dysregulation and promote the recruitment and survival of disseminated tumor cells. We have employed drug-free poly(lactide-co-glycolide) (PLGA) nanoparticles, ONP-302, to modulate myeloid cell phenotypes and trafficking to disrupt the formation of the metastatic niche. The anti-metastatic efficacy of ONP-302 nanoparticles was evaluated in a translationally relevant mouse model of orthotopic triple-negative breast cancer. Methods: ONP-302 nanoparticles were evaluated in the syngeneic 4T1 model of triple-negative breast cancer in female BALB/c or RAG1KO BALB/c mice. ONP-302 nanoparticles intravenously injected into tumor-bearing mice every 3 days starting 1 day after tumor inoculation. Lungs were extracted 14 and 21 days after inoculation for analysis by single cell RNA sequencing and quantification of metastases by luminescent imaging, respectively. In resection studies, primary tumors were resected 11 days after inoculation and tissues were extracted 42 days after resection for quantification of metastases. Results: ONP-302 nanoparticles significantly reduced primary tumor growth and completely inhibited the formation of lung metastases. ONP-302 was also effective at suppressing metastasis when applied following surgical resection. In mice which received ONP-302 after surgical resection, lung metastases were undetectable up to 42 days after resection, while 44% of control mice developed metastases. These findings suggest that ONP-302 targets both primary tumor growth and metastatic colonization. Single cell RNA sequencing was employed to analyze ONP-302 modulation of the lung metastatic niche. The lungs of ONP-302 treated mice had lower neutrophil infiltration and a higher proportion of monocytes and dendritic cells compared to control mice. Gene expression pathways associated with inflammatory interferon and tumor necrosis factor responses were upregulated in neutrophils, monocytes, and dendritic cells from ONP-302 treated mice. The upregulation of these pathways suggests that ONP-302 treatment prevents the formation of an immunosuppressive niche and promotes anti-tumor cytotoxicity. Adaptive immunity was essential for ONP-302 efficacy, as T and B cell deficient RAG1KO mice demonstrated complete loss of ONP-302 efficacy both in slowing primary tumor growth and preventing metastasis. Conclusions: Our findings demonstrate that our drug-free PLG nanoparticles, ONP-302, impede cancer metastasis as a monotherapy by inhibiting the accumulation of immunosuppressive myeloid cells." @default.
• W4286296033 created "2022-07-21" @default.
• W4286296033 creator A5002687023 @default.
• W4286296033 creator A5004136451 @default.
• W4286296033 creator A5013258223 @default.
• W4286296033 creator A5016427677 @default.
• W4286296033 creator A5032600992 @default.
• W4286296033 creator A5060240190 @default.
• W4286296033 creator A5069703075 @default.
• W4286296033 creator A5074563342 @default.
• W4286296033 date "2022-06-01" @default.
• W4286296033 modified "2023-09-27" @default.
• W4286296033 title "Drug-free biodegradable nanoparticles alleviate myeloid cell-induced immunosuppression and inhibit metastasis." @default.
• W4286296033 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e14555" @default.
• W4286296033 hasPublicationYear "2022" @default.
• W4286296033 type Work @default.
• W4286296033 citedByCount "0" @default.
• W4286296033 crossrefType "journal-article" @default.
• W4286296033 hasAuthorship W4286296033A5002687023 @default.
• W4286296033 hasAuthorship W4286296033A5004136451 @default.
• W4286296033 hasAuthorship W4286296033A5013258223 @default.
• W4286296033 hasAuthorship W4286296033A5016427677 @default.
• W4286296033 hasAuthorship W4286296033A5032600992 @default.
• W4286296033 hasAuthorship W4286296033A5060240190 @default.
• W4286296033 hasAuthorship W4286296033A5069703075 @default.
• W4286296033 hasAuthorship W4286296033A5074563342 @default.
• W4286296033 hasConcept C121608353 @default.
• W4286296033 hasConcept C126322002 @default.
• W4286296033 hasConcept C142724271 @default.
• W4286296033 hasConcept C203014093 @default.
• W4286296033 hasConcept C2775930923 @default.
• W4286296033 hasConcept C2779013556 @default.
• W4286296033 hasConcept C2779282312 @default.
• W4286296033 hasConcept C2780283643 @default.
• W4286296033 hasConcept C502942594 @default.
• W4286296033 hasConcept C530470458 @default.
• W4286296033 hasConcept C71924100 @default.
• W4286296033 hasConcept C8891405 @default.
• W4286296033 hasConceptScore W4286296033C121608353 @default.
• W4286296033 hasConceptScore W4286296033C126322002 @default.
• W4286296033 hasConceptScore W4286296033C142724271 @default.
• W4286296033 hasConceptScore W4286296033C203014093 @default.
• W4286296033 hasConceptScore W4286296033C2775930923 @default.
• W4286296033 hasConceptScore W4286296033C2779013556 @default.
• W4286296033 hasConceptScore W4286296033C2779282312 @default.
• W4286296033 hasConceptScore W4286296033C2780283643 @default.
• W4286296033 hasConceptScore W4286296033C502942594 @default.
• W4286296033 hasConceptScore W4286296033C530470458 @default.
• W4286296033 hasConceptScore W4286296033C71924100 @default.
• W4286296033 hasConceptScore W4286296033C8891405 @default.
• W4286296033 hasFunder F4320319308 @default.
• W4286296033 hasIssue "16_suppl" @default.
• W4286296033 hasLocation W42862960331 @default.
• W4286296033 hasOpenAccess W4286296033 @default.
• W4286296033 hasPrimaryLocation W42862960331 @default.
• W4286296033 hasRelatedWork W2012296077 @default.
• W4286296033 hasRelatedWork W2201476026 @default.
• W4286296033 hasRelatedWork W2206223252 @default.
• W4286296033 hasRelatedWork W2624337995 @default.
• W4286296033 hasRelatedWork W2904294837 @default.
• W4286296033 hasRelatedWork W3033874287 @default.
• W4286296033 hasRelatedWork W3088410393 @default.
• W4286296033 hasRelatedWork W3183783449 @default.
• W4286296033 hasRelatedWork W4232329232 @default.
• W4286296033 hasRelatedWork W1606523365 @default.
• W4286296033 hasVolume "40" @default.
• W4286296033 isParatext "false" @default.
• W4286296033 isRetracted "false" @default.
• W4286296033 workType "article" @default.